Faron Pharmaceuticals Oy (LON:FARN) (NASDAQFIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after announcing they're donating interferon beta-1a drug supplies to treat 2,000 patients taking part in a globally crucial coronavirus (COVID-19) study.
The World Health Organisation's Solidarity trial is assessing four drug options, including the Faron candidate, known as Traumakine.
Jalkanen also talks through their recent £12.18mln (€14mln) fundraise which will mainly be used to expand the current phase I/II MATINS trial of its Clevegen precision immunotherapy candidate.